| Page 1406 | Kisaco Research
 

Dr Rand Hindi

Co-Founder and CEO
Zama

Dr Rand Hindi is an entrepreneur and deeptech investor. He is the CEO at Zama, an open source homomorphic encryption company, and an investor in 30+ companies across privacy, AI, blockchain, medtech and psychedelics. Rand started coding at the age of 10, founded a Social Network at 14 and a web agency at 15 before getting into Machine Learning at 18 and starting a PhD at 21. He then created Snips, the first edge-based, private by design voice solution for OEMs, which was then acquired by Sonos.

Dr Rand Hindi

Co-Founder and CEO
Zama

Dr Rand Hindi

Co-Founder and CEO
Zama

Dr Rand Hindi is an entrepreneur and deeptech investor. He is the CEO at Zama, an open source homomorphic encryption company, and an investor in 30+ companies across privacy, AI, blockchain, medtech and psychedelics. Rand started coding at the age of 10, founded a Social Network at 14 and a web agency at 15 before getting into Machine Learning at 18 and starting a PhD at 21. He then created Snips, the first edge-based, private by design voice solution for OEMs, which was then acquired by Sonos. He has been elected as a TR35 by the MIT Technology Review, as a "30 under 30" by Forbes, is a lecturer at Sciences Po in Paris and an advisor to multiple companies. He was previously a member of the French Digital Council where he focused on AI and Privacy issues. He holds a BSc in Computer Science and a PhD in Bioinformatics from University College London (UCL), as well as two graduate degrees from Singularity University in Silicon Valley and THNK in Amsterdam.

 

Dr. Amy Li

Head of Research and Innovation
PetMedix

Dr. Amy Li

Head of Research and Innovation
PetMedix

Dr. Amy Li

Head of Research and Innovation
PetMedix
 

Wouter Bruins

Managing Director
In Ovo

Wouter Bruins

Managing Director
In Ovo

Wouter Bruins

Managing Director
In Ovo
 

Daniel Oliver

CEO and Founder
Rejuvenate Bio

Daniel Oliver

CEO and Founder
Rejuvenate Bio

Daniel Oliver

CEO and Founder
Rejuvenate Bio
 

Lori Teller

Clinical Associate Professor Telehealth
Texas A&M University College of Veterinary Medicine and Biomedical Sciences

Lori Teller

Clinical Associate Professor Telehealth
Texas A&M University College of Veterinary Medicine and Biomedical Sciences

Lori Teller

Clinical Associate Professor Telehealth
Texas A&M University College of Veterinary Medicine and Biomedical Sciences
Q&A with Stefano Zanotti, Dyne Therapeutics

Q&A with Stefano Zanotti, Dyne Therapeutics

1. Please introduce yourself and your role at Dyne Therapeutics.

Stefano Zanotti, head of neuromuscular research at Dyne Therapeutics, a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

In my role, I oversee a multidisciplinary research team focused on the preclinical development of treatments for genetically driven neuromuscular diseases. We are responsible for the progress of our preclinical programs, leading up to a nomination of a potential clinical candidate.

Anjuna - Scalability and Security in the Cloud: Israel Ministry of Defense
 

Jim Mellon

Co-Founder
Agronomics

Jim Mellon is a British entrepreneur, investor and philanthropist with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies.

Jim Mellon

Co-Founder
Agronomics

Jim Mellon

Co-Founder
Agronomics

Jim Mellon is a British entrepreneur, investor and philanthropist with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies.
Jim’s investment philosophy is underpinned by careful analysis of new industries or major shifts in markets. This includes the global financial crisis of 2008-2009, as foreseen in the first book Jim co-authored entitled Wake Up!, and subsequently in the book Juvenescence which marked the beginning of a rush of capital into the nascent field of ageing research and also led to the formation of the company Juvenescence with his partners. Juvenescence is a leading biopharma company in the commercialisation of therapies to slow, stop and reverse aging.
More recently Jim authored the book Moo’s Law, focusing on investment opportunities in the field of cellular agriculture - the production of proteins and materials directly from cells. Jim co-founded Agronomics to invest in a portfolio of leading companies in cellular agriculture and is its largest investor.
Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and of the American Federation for Aging Research (AFAR). He is also a trustee of Biogerontology Research Foundation and is an Honorary Fellow of Oriel College at the University of Oxford, where he has established the Mellon Centre for Longevity, and Jim also sits on the Advisory Board of the Milken Institute’s Centre for the Future of Aging.